Personal information

No personal information available

Activities

Collapse all

Works (21)

Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.c.7122905
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.c.7122905.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

Clinical Cancer Research
2024-03-15 | Journal article
DOI: 10.1158/1078-0432.CCR-23-2568
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415564.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415564
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415561.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415561
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415558.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415558
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415555
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415555.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415552
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415552.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415549.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415549
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S4 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415546.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S4 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415546
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415543
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415543.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415540
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref

Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

2024-03-15 | Preprint
DOI: 10.1158/1078-0432.25415540.v1
Contributors: Shinji Nakamichi; Kaoru Kubota; Toshihiro Misumi; Tetsuro Kondo; Shuji Murakami; Yoshimasa Shiraishi; Hisao Imai; Daijiro Harada; Kazutoshi Isobe; Hidetoshi Itani et al.
Source: check_circle
Crossref
How many people are using ORCID?